1. Electronic Components & Sensors
Not in registry
Source Critical for continuous glucose monitors, implantable devices, and connected medical products.
Confidence: high
ABT
T2S&P 500Health Care (XLV)Value (IWD)Abbott Laboratories
Child Care '24: Child HealthcareData Owners '25: Healthcare, Claims & Clinical DataDiagnostics '26: Broad Diagnostic Platforms & LabsDiagnostics '26: Cancer Screening & Early DetectionDiagnostics '26: Infectious Disease TestingDiagnostics '26: Point-of-Care & Rapid DiagnosticsMedTech Long '25: Wearable HealthMedTech Long '26: Diagnostics & Early Detection
Loading chart…
OverviewAbbott Laboratories is a global healthcare company offering medical devices (~48%), diagnostic products (~20%), established pharmaceuticals (~13%), and nutritio
Abbott Laboratories is a global healthcare company offering medical devices (~48%), diagnostic products (~20%), established pharmaceuticals (~13%), and nutritional products (~19%). Serving hospitals, labs, and consumers, it addresses diverse health needs. Abbott recently announced plans to spin off its nutrition business by late 2027, aiming to sharpen its focus on higher-growth, higher-margin segments.
Key Inputs And Sourcing
2. Specialized Medical Materials (Polymers, Metals)
Not in registry
Source Includes polymers, metals, catheters, valves, and lead systems for medical devices.
Confidence: high
3. Diagnostic Reagents & Chemicals
Not in registry
Source Essential for diagnostic instruments and testing consumables.
Confidence: high
4. Nutrition Ingredients (e.g., Dairy, Proteins)
Not in registry
Source Includes dairy-based and other food ingredients, and nutritional additives for products like Similac (made with whole milk).
Confidence: high
5. Active Pharmaceutical Ingredients (APIs) & Excipients
Not in registry
Source Important for established pharmaceutical products; Abbott manufactures and supplies APIs.
Confidence: high
6. Packaging Materials
Not in registry
Source Includes sterile packaging for medical devices and general packaging for nutrition products.
Confidence: medium
7. Manufacturing Labor
Not in registryaccess=api
Source A significant component of COGS for manufacturing-intensive businesses across all segments. Abbott's nutrition business alone has 16,000 employees.
Confidence: medium
8. Logistics & Distribution
Not in registry
Source Critical for global delivery reliability, with Abbott operating in over 160 countries and working with 75,000+ suppliers.
Confidence: medium
9. Energy
Not in registry
Source Required for manufacturing operations across Abbott's global facilities.
Confidence: low
Industry Publications
- MD+DI (Medical Device and Diagnostics Industry) (mddionline.com) — Provides educational content and in-depth analysis of medical device and diagnostics production, regulations, and innovations, directly relevant to Abbott's largest segments.
- Fierce Pharma (fiercepharma.com) — Reports on all aspects of the pharmaceutical industry, from drug development to regulatory approvals and manufacturing, crucial for monitoring Abbott's Established Pharmaceutical Products segment.
- Nutritional Outlook (nutritionaloutlook.com) — Focuses specifically on the nutrition industry, covering ingredients, market trends, and regulatory issues, which is highly relevant for Abbott's significant nutrition business.
- MedTech Insight (medtechinsight.com) — Delivers contextualized reporting on device, diagnostic, and digital health advancements, market dynamics, and industry data, offering deep insights into Abbott's core MedTech and Diagnostics businesses.
- Diagnostics World News (diagnosticsworldnews.com) — Serves as a resource for advancements in diagnostics, covering genetic tests, clinical trials, and industry events, directly pertinent to Abbott's Diagnostic Products division.
Economic Data Watch
1. FRED — National Health Expenditure Accounts
Matchedfred · access=api · map_only
Cadence monthly
Why it matters Overall healthcare spending indicates the market size and health for diagnostic and medical device services, directly impacting Abbott's addressable market.
Signal to watch Increasing healthcare expenditures (HTOTEXP) would be bullish, indicating a growing market for Abbott's products.
Confidence: low
2. FRED — Retail Sales: Total
Matchedfred · access=api · map_only
Cadence monthly
Why it matters Reflects consumer spending trends, which are relevant for Abbott's consumer-facing nutrition products and over-the-counter diagnostics.
Signal to watch Strong or accelerating retail sales (RSXFS) would be bullish, suggesting healthy consumer demand for nutritional products.
Confidence: low
3. FRED — World Bank: Population ages 65 and above (% of total population)
Matchedfred · access=api · map_only
Metric/field SP.POP.65UP.TO.ZS
Cadence monthly
Why it matters An aging global population is a key durable healthcare trend driving demand for Abbott's medical devices, diagnostics, and adult nutrition products.
Signal to watch An increasing percentage of the population aged 65 and above (SP.POP.65UP.TO.ZS) would be bullish, indicating a growing demographic for Abbott's core markets.
Confidence: high
4. Trading Economics — Japan Industrial Production
Not in registryaccess=scrape
Metric/field Japan Industrial Production
Cadence monthly
Why it matters Japan is a significant international market for Abbott, with new product launches like the Volt PFA catheter expected in Q4. Industrial production can be a proxy for overall economic health and healthcare infrastructure investment.
Signal to watch Rising industrial production in Japan would be bullish, suggesting a healthy economic environment supportive of healthcare spending and product adoption.
Confidence: high
5. Trading Economics — India GDP Growth Rate
Not in registryaccess=scrape
Metric/field India GDP Growth
Cadence quarterly
Why it matters Abbott's Established Pharmaceutical Products (EPD) business shows strong growth in emerging markets like India. GDP growth indicates economic expansion and potential for increased healthcare access.
Signal to watch Sustained or accelerating GDP growth in India would be bullish, indicating a favorable economic environment for Abbott's EPD and other businesses in the region.
Confidence: high
Free Alt Data Watch
1. FDA — Medical Device 510(k) Clearances and PMA Approvals
Not in registry
Metric/field device_name, decision_date
Cadence daily
Why it matters FDA approvals and clearances are critical for launching new medical devices and diagnostics, directly impacting Abbott's revenue growth and market penetration.
Signal to watch Frequent and timely FDA clearances/approvals for Abbott's pipeline products (e.g., Amulet 360, TactiFlex Duo, Libre Duo) would be bullish, indicating successful R&D and market access.
Confidence: high
2. ClinicalTrials.gov — Clinical Trial Status and Enrollment
Not in registry
Metric/field overall_status, study_type, condition
Cadence daily
Why it matters Tracking the progress of clinical trials provides insight into Abbott's R&D pipeline, potential future product launches, and evidence generation for existing products.
Signal to watch Advancing trials to later stages, positive enrollment trends, and successful completion of key studies (e.g., AVEIR CSP, mitral replacement valve) would be bullish, signaling a robust pipeline.
Confidence: high
3. USPTO PatentsView — Patent Grants by Assignee
Not in registry
Metric/field patent_number, grant_date, patent_title
Cadence weekly
Why it matters Patent grants indicate Abbott's innovation output and intellectual property protection, which are crucial for maintaining competitive advantage in MedTech and Diagnostics.
Signal to watch A consistent volume of new patent grants would be bullish, demonstrating ongoing innovation and strengthening Abbott's market position.
Confidence: high
4. Google Trends — Search Interest
Not in registry
Metric/field search_interest_index for 'FreeStyle Libre'
Cadence weekly
Why it matters Search interest for key products like FreeStyle Libre can serve as a proxy for consumer awareness, interest, and potential adoption of continuous glucose monitoring.
Signal to watch Increasing or sustained high search interest for 'FreeStyle Libre' would be bullish, suggesting strong market demand and brand recognition.
Confidence: medium
5. USASpending.gov — Federal Contract Awards
Not in registryaccess=api
Metric/field total_obligated_amount, award_id, product_or_service_code
Cadence daily
Why it matters Federal contract awards can indicate government procurement of Abbott's products, particularly in areas like diagnostics, nutrition (e.g., WIC contracts), or medical supplies.
Signal to watch Consistent or increasing federal contract awards to Abbott Laboratories would be bullish, indicating stable government demand and market presence.
Confidence: high
Paid Alt Data Watch
1. IQVIA — Medical Claims Data
Matchediqvia_medical_claims · access=file · map_only
Metric/field CPT code utilization for CGM (e.g., 95250, 95251), LAA closure (e.g., 33340), colorectal cancer screening (e.g., 81528)
Cadence monthly
Why it matters Provides granular, independent data on actual test utilization, procedure volumes, market share, and reimbursement trends for Abbott's key medical devices and diagnostic tests.
Signal to watch Increasing CPT code utilization for Abbott-relevant procedures and tests would be bullish, indicating strong product adoption and market growth.
Confidence: high
2. Definitive Healthcare — PhysicianView
Not in registry
Metric/field physician_adoption_rate for new Abbott medical devices (e.g., Volt PFA catheter, Amulet 360)
Cadence monthly
Why it matters Tracks the adoption and utilization of new Abbott medical devices by healthcare providers, offering insights into market penetration and competitive positioning.
Signal to watch Accelerating physician adoption rates for newly launched Abbott devices would be bullish, indicating successful commercialization and strong product reception.
Confidence: medium
3. Sensor Tower — App Intelligence
Not in registry
Metric/field daily_active_users (DAU) and download_rank for 'FreeStyle LibreLink' app
Cadence daily
Why it matters The FreeStyle LibreLink app is integral to the FreeStyle Libre CGM ecosystem. Tracking its DAU and download rank provides insights into user engagement and new user acquisition.
Signal to watch Increasing DAU and improving download ranks for the FreeStyle LibreLink app would be bullish, indicating growing user base and engagement with Abbott's CGM platform.
Confidence: medium
4. Indeed Hiring Lab — Job Postings Data
Matched (medium)iri_retail_pos_scanner_data · access=file · map_only
Metric/field job_posting_count for 'Abbott Laboratories' filtered by 'sales' or 'R&D' in 'Medical Devices' or 'Diagnostics' segments
Cadence monthly
Why it matters Hiring trends, particularly in sales and R&D for key growth segments, can signal Abbott's investment in commercialization efforts and future innovation.
Signal to watch Increasing job postings in sales and R&D for Abbott's Medical Devices and Diagnostics segments would be bullish, indicating strategic investment and growth initiatives.
Confidence: medium
5. Earnest Analytics — Transaction Data
Matched (medium)earnest_analytics_credit_debit_card_consumer_spend · access=file · map_only
Metric/field consumer_spending_volume for 'Ensure', 'Similac', 'Pedialyte' brands
Cadence monthly
Why it matters Provides real-time insights into consumer purchasing behavior for Abbott's key nutrition brands, reflecting market demand and competitive performance.
Signal to watch Consistent or increasing consumer spending volume on Abbott's nutrition brands would be bullish, indicating strong market demand and brand loyalty.
Confidence: medium
Search Keywords Brand Product
- Volt PFA catheter
- TactiFlex Duo catheter
- Amulet 360
- Libre Duo
- FreeStyle Libre
- Cologuard
- Cologuard Plus
- AVEIR pacemaker
- CardioMEMS
- medical devices
- diagnostics
- established pharmaceuticals
- electrophysiology
- diabetes care
- cancer screening
- left atrial appendage closure
- continuous glucose monitoring
- nutrition business spin-off
Search Keywords Event Phrases
- Abbott Q3 2026 earnings
- Nutrition business separation
Search Keywords Policy Regulatory
- FDA approval
- CMS reimbursement
- WIC contracts
- What They Do (Plain English & Analogies)
- Abbott Laboratories is like a diversified healthcare company that helps people live healthier lives. They create and sell a wide range of products across different areas of healthcare. Think of them as a company focused on fixing and monitoring the human body, as well as diagnosing what's wrong. They make advanced medical devices, like pacemakers for hearts, devices to prevent strokes, and continuous glucose monitors for people with diabetes. They also develop diagnostic tests, which are like health detectives, helping doctors find out what's going on inside your body, from detecting cancer early to identifying infections. Additionally, they provide established generic medicines, primarily in markets outside the U.S. Recently, Abbott announced plans to separate its nutrition business (which makes products like baby formula and adult nutritional shakes) into its own independent company, allowing Abbott to focus even more on its medical technology, diagnostics, and pharmaceutical segments.
- Very Brief History
- Founded in 1888 by Dr. Wallace Calvin Abbott in Chicago, Illinois, Abbott Laboratories began as a pharmaceutical company. Over its long history, it has evolved into a diversified global healthcare enterprise, expanding significantly into medical devices, diagnostics, and nutritional products. A key milestone was the spin-off of its research-based pharmaceutical business into AbbVie in 2013, allowing Abbott to focus on its medical device, diagnostics, nutrition, and established pharmaceuticals segments. In 2026, Abbott announced its intention to spin off its nutrition business into an independent, publicly traded company.
- "Street Stereotype"
- Abbott is generally perceived by investors and analysts as a highly diversified and resilient global healthcare leader with a strong, innovative pipeline. The "street" views it as a company capable of delivering consistent growth, particularly in its medical devices and diagnostics segments. Post-nutrition spin-off, the stereotype is evolving towards an even more focused, higher-growth, and higher-margin innovation-driven healthcare company.
- Subsidiaries On Linked In*
- Abbott Laboratories — Main company page; LinkedIn: https://www.linkedin.com/company/abbott-/
- Exact Sciences Corporation — Acquired in March 2026, contributing to cancer diagnostics.; LinkedIn: https://www.linkedin.com/company/exact-sciences/
- Customer Sectors & Example Clients
- Abbott's customers span various healthcare sectors, including hospitals, clinical laboratories, physician offices, urgent care centers, pharmacies, and government health programs. They also serve individual consumers directly with self-test systems. Example clients would include large hospital networks (e.g., those utilizing their core laboratory diagnostic instruments and medical devices), government programs (e.g., for diagnostic testing), and individual patients (e.g., purchasing FreeStyle Libre).
- New Customers / Segments They'Re Targeting
- Abbott is targeting new customer segments by expanding options for colorectal cancer screening with the launch of its first blood-based test, aiming to reach more people who might not opt for stool-based screening. In diabetes care, they are working to penetrate the Type 2 non-insulin population for continuous glucose monitoring (CGM), although this faces challenges in the absence of broader reimbursement expansion. Internationally, they are actively pursuing reimbursement expansion for Libre CGM in numerous countries. The company is also expanding into new areas within diagnostics, such as precision oncology and minimal residual disease (MRD) testing.
- Sales Geographies And Expansion Plans
- Abbott currently sells its products worldwide, with significant operations across the United States, Europe, Japan, Latin America, Asia, and the Middle East. The company is actively expanding its medical device sales, particularly with new PFA catheters in Europe and a planned launch of the Volt PFA catheter in Japan in Q4 2026. They also plan to bring the new Amulet 360 left atrial appendage device to the U.S. market. International growth for their Established Pharmaceutical Products (EPD) is broad-based across emerging markets, including several countries in Asia, Latin America, and the Middle East. For cancer diagnostics, they have selected specific international markets for expansion.
- How Key Themes May Help/Hurt
- The "MedTech Long '26: Diagnostics & Early Detection" theme strongly benefits Abbott. As a leader in diagnostics, particularly with its cancer diagnostics business (Exact Sciences acquisition and Cologuard), Abbott is directly aligned with the accelerating technological advancements in genomics and multiomics, which drive the development of highly effective diagnostic and early detection technologies. The increasing global prevalence of chronic diseases, especially cancer, and an aging population create a sustained demand for advanced diagnostic solutions and proactive health monitoring, fueling the need for Abbott's early detection tests. Favorable regulatory developments and expanding coverage for novel assays, such as the potential for broader reimbursement for cancer screening tests, enhance market access and accelerate adoption for Abbott's products. However, persistent reimbursement pressures and evolving payer policies, including potential ASP declines and delayed coverage for novel tests, could hurt profitability and market uptake for some of Abbott's diagnostic offerings.
3 Main Long-Term Bull Details
- Innovation-Driven Portfolio and Robust Pipeline: Abbott's strategy to focus on higher-growth, higher-margin businesses in MedTech, diagnostics, and Established Pharmaceuticals, powered by technology and innovation, positions it for accelerated sales growth and margin expansion post-nutrition spin-off. The company boasts an industry-leading pipeline with multiple new product approvals and launches, such as the Volt PFA catheter, TactiFlex Duo catheter, Amulet 360, and Libre Duo, which are expected to drive sustainable growth for years to come.
- Market Leadership in Attractive Healthcare Areas: Abbott holds market-leading positions in three of the most attractive areas of healthcare: MedTech, diagnostics, and Established Pharmaceuticals. This diversified leadership, aligned with durable healthcare trends like an aging population and increasing chronic disease prevalence, provides resilience and multiple engines for sustained performance.
- Strong Financial Profile and Capital Allocation: Abbott consistently generates strong earnings growth and cash flow, enabling continued investment in its pipeline, dividend growth, and strategic M&A. The planned capital structures for both Abbott and the new nutrition company are designed to ensure strong financial foundations and investment-grade credit ratings, providing flexibility for future growth initiatives.
3 Main Long-Term Bear Details
- Intensifying Competitive Pressures: Abbott faces significant competitive intensity across key medical device markets, such as the LAA closure market where a competitor holds dominant share, and in continuous glucose monitoring (CGM) where international pricing pressures are increasing. This competition can lead to pricing pressures, increased commercialization costs, and challenges in market share capture.
- Reimbursement and Regulatory Uncertainties: The exact timing and scope of crucial reimbursement expansions, such as for Type 2 non-insulin Medicare coverage for Libre CGM, remain uncertain and difficult to forecast. Delays or unfavorable decisions in payer policies and regulatory approvals can impact market access and adoption rates for new technologies, affecting near-term revenue acceleration.
- Impact of External Factors and Market Dynamics: While the nutrition business is being spun off, other segments can still be vulnerable to external factors. For example, the rapid and molecular diagnostics segment has experienced sales declines due to weaker-than-normal respiratory seasons. Geopolitical and economic volatility around the globe also presents challenges in navigating operating environments.
- Competitors And Differentiation
- Abbott faces competition across its segments. In the left atrial appendage (LAA) closure market, a competitor holds a dominant market share, and Abbott's Amulet 360 aims to capture share by offering a competitive product with ease of use and superior seal technology. In continuous glucose monitoring (CGM), they face pricing pressure in international markets due to increased competition, but differentiate through scale, manufacturing setup, and product innovation like Libre Duo. In cancer diagnostics, while Cologuard is a market leader, Abbott is expanding its portfolio to include blood-based screening to offer a broader range of options, positioning itself as the only company with both stool-based and blood-based screening. Their overall differentiation strategy relies on a broad, diversified portfolio, continuous innovation, and market-leading positions in MedTech, diagnostics, and Established Pharmaceuticals.
- Recent Performance & What The Market'S Focused On
- Abbott delivered an acceleration in growth on both the top and bottom lines in the third quarter of 2026, with sales growing 7% and earnings per share growing 9%. Diagnostics sales grew 6.5%, Nutrition sales grew 5%, Established Pharmaceutical Products (EPD) sales increased 8.5%, and Medical Devices sales grew 8%. However, the company adjusted its Q4 revenue guidance, implying about 8% growth, primarily due to short-term headwinds in Electrophysiology (LAA market dynamics and customers awaiting new products) and Diabetes Care (challenges in penetrating the Type 2 population without reimbursement expansion and international pricing pressure). The market is primarily focused on the announced intention to separate the nutrition business into an independent, publicly traded company, the implications of this spin-off for Abbott's future growth profile and margins, and the company's outlook for 2027, including its sales and EPS guidance. Investors are also closely watching the performance of new product launches like the Volt PFA catheter, TactiFlex Duo catheter, Amulet 360, and Libre Duo.
- Revenue Segments And Estimated Mix
- Medical Devices — Mix: ~58%; Source: Post-nutrition spin-off estimate based on 2024 revenues and Q3 2026 transcript; Trend: Grew 8% in Q3 2026, led by double-digit growth in electrophysiology and rhythm management. Diabetes care grew 8%.
- Diagnostic Products — Mix: ~26%; Source: Post-nutrition spin-off estimate based on 2024 revenues and Q3 2026 transcript; Trend: Grew 6.5% in Q3 2026, driven by core laboratory and cancer diagnostic businesses. Cancer diagnostics grew 14%.
- Established Pharmaceutical Products (EPD) — Mix: ~16%; Source: Post-nutrition spin-off estimate based on 2024 revenues and Q3 2026 transcript; Trend: Increased 8.5% in Q3 2026, with broad-based growth across geographies and therapeutic areas in emerging markets.
- Product Brands
- Cologuard
- Cologuard Plus
- Libre Duo
- FreeStyle Libre
- i-STAT
- Alinity
- Architect
- IDNOW
- Panbio
- Assert-IQ
- BinaxNOW
- SimpleScreen CRC
- GLP systems Track
- Volt PFA catheter
- TactiFlex Duo catheter
- Amulet 360
- Avera pacemaker
- CardioMEMS HF System
- TriClip
- MitraClip
- Absolute Pro Vascular Self-Expanding Stent System
- Acculink Carotid Stent System
- ACCUNET Embolic Protection System
- Advisor HD Grid Mapping Catheter Sensor Enabled
- Agilis NxT Steerable Introducers
- Amplatzer Duct Occluders
- Amplatzer Talisman PFO Occluder
- Amplatzer Piccolo Occluder
- Amplatzer Septal Occluder
- Amplatzer VSD Occluders
- Armada PTA Catheter
- Clarithromycin
Bull / Bear DetailsAbbott Laboratories maintains a bullish outlook as of 2026-10-22, driven by its strategic decision to spin off the Nutrition business, which is expected to acce
Thesis
Abbott Laboratories maintains a bullish outlook as of 2026-10-22, driven by its strategic decision to spin off the Nutrition business, which is expected to accelerate sales growth and expand margin profiles for the remaining MedTech, Diagnostics, and Established Pharmaceuticals portfolio. A robust pipeline of innovative products, particularly in Electrophysiology, Diabetes Care, and Cancer Diagnostics, alongside strong Q3 performance, underpins sustainable long-term growth despite near-term market and reimbursement challenges.
Bull case
The planned spin-off of the Nutrition business by late 2027 is a significant strategic move expected to accelerate Abbott's sales growth by 50-100 basis points and expand gross and operating margins by over 200 and 100 basis points, respectively. This refines Abbott's portfolio towards higher-growth, higher-margin businesses, enhancing shareholder value and strategic focus.
Abbott boasts a robust and actively advancing innovation pipeline across its core segments. Recent FDA approvals and launches for products like the TactiFlex Duo catheter, Libre Duo (dual glucose ketone sensor), and the upcoming Amulet 360 LAA device, along with new cancer diagnostic tests and biosimilars, are poised to drive sustainable growth and market share gains.
The Cancer Diagnostics segment, bolstered by Exact Sciences, continues strong performance with 14% sales growth in Q3. Abbott's unique position offering both stool-based (Cologuard) and newly launched blood-based colorectal cancer screening tests expands market reach and solidifies its leadership in early detection, contributing to margin expansion.
Bear case
Abbott faces short-term headwinds in key medical device markets. Electrophysiology growth is impacted by LAA market dynamics and accounts deferring orders while awaiting the new Amulet 360 device. Additionally, the Diabetes Care segment is experiencing increased international pricing pressure, which may mute volume growth in the near term.
The timing of significant reimbursement expansion for Libre CGM, particularly for Type 2 non-insulin users in the U.S., remains uncertain. This unpredictability in payer policies could lead to temporary plateaus in CGM growth rates, impacting near-term revenue acceleration despite strong clinical data supporting broader adoption.
Abbott's initial sales outlook for 2027 is conservative, forecasting growth similar to 2026, despite numerous product launches and expected acceleration. External factors like the July cybersecurity event, which cost approximately one point of Q3 growth in cancer diagnostics, highlight ongoing vulnerabilities to operational disruptions.
Bull / Bear Case
- Bear Case
- Abbott faces several near-term headwinds that temper its outlook. The Electrophysiology segment is experiencing short-term challenges due to LAA market dynamics and customers deferring orders while awaiting the new Amulet 360 device. Additionally, the Diabetes Care segment is encountering increased international pricing pressure, which is expected to mute volume growth in the near term, and the timing of significant U.S. reimbursement expansion for Type 2 non-insulin CGM users remains uncertain. Management's initial sales outlook for 2027 is conservative, forecasting growth similar to 2026 despite numerous product launches. Operational disruptions, such as the July cybersecurity event that impacted Q3 cancer diagnostics growth by approximately one point, highlight ongoing vulnerabilities.
- Bull Case
- Abbott Laboratories presents a compelling bull case driven by its strategic decision to spin off the Nutrition business by late 2027, which is projected to accelerate sales growth by 50-100 basis points and expand gross and operating margins by over 200 and 100 basis points, respectively. This move is expected to sharpen Abbott's focus on higher-growth, higher-margin segments like MedTech, Diagnostics, and Established Pharmaceuticals. The company boasts a robust innovation pipeline, with recent FDA approvals and launches for products such as the TactiFlex Duo catheter, Libre Duo, and the upcoming Amulet 360 LAA device, alongside new cancer diagnostic tests and biosimilars, poised to drive sustainable growth and market share gains. Strong Q3 performance, with 7% sales growth and 9% EPS growth, further underpins confidence in its long-term trajectory.
- More Compelling & Why
- Bull. The strategic spin-off of the Nutrition business is a transformative move expected to accelerate sales growth and significantly expand margin profiles for the remaining core businesses. This long-term value creation, coupled with a robust innovation pipeline and an EV/EBITDA (TTM) of 17.60x (13% below its 10-year median), makes the bull case more compelling despite near-term headwinds. A sustained deceleration in core MedTech and Diagnostics sales growth, or a material delay in realizing the anticipated margin expansion post-spin, would flip my view.
Key Factors
| Key Factor | Why It Matters | What To Watch | What It Signals | Where/How To Track | Free Alt Data | Paid Alt Data |
|---|---|---|---|---|---|---|
| US Medicare Coverage Expansion for Libre CGM (Type 2 Non-Insulin) | Expanded Medicare coverage for Libre CGM for Type 2 non-insulin users represents a massive untapped market opportunity, potentially unlocking around 10 million Medicare beneficiaries and significantly accelerating CGM sales growth. | Monitor announcements from CMS regarding expanded Medicare coverage for Libre CGM for Type 2 non-insulin users, including the effective date and the specific patient population covered. | Bullish: Official announcement of Medicare coverage for Libre CGM for Type 2 non-insulin users, especially if it aligns with or exceeds the anticipated 10 million Medicare beneficiaries. | CMS official announcements, Abbott's earnings calls, and industry news outlets. While not factored into current forecasts, the clinical support for this expansion is strong. | 1. Google Trends — Search InterestNot in registry Metric/field Search term volume for 'Libre CGM Type 2 non-insulin' AND 'Medicare coverage' Cadence weekly Why it matters Indicates public and physician interest and awareness, signaling potential market adoption and policy discussions. Signal to watch Sustained increase in search interest, particularly from healthcare professionals or patient advocacy groups. Confidence: Medium | 1. IQVIA / Symphony Health — Medical Claims DataMatchediqvia_medical_claims · access=file · map_only Metric/field CPT code utilization for continuous glucose monitoring (e.g., specific codes for Libre) for Type 2 non-insulin patients Cadence irregular Why it matters Provides granular, independent data on actual test utilization, market share, and reimbursement trends, indicating early signs of coverage or adoption. Signal to watch Increase in claims for CGM among Type 2 non-insulin patients, suggesting expanded coverage or physician prescribing patterns. Confidence: High |
| FDA Approval and US Launch of Amulet 360 Left Atrial Appendage (LAA) Device | Amulet 360 is crucial for Abbott to regain market share in the LAA closure market, which is currently a short-term headwind for its Electrophysiology business. Its launch is expected to reignite growth and capture share. | Watch for the official FDA approval announcement for Amulet 360 and subsequent company communications regarding its broad U.S. commercial launch. Initial physician feedback on ease of use and outcomes will be key. | Bullish: FDA approval and a successful broad U.S. launch in Q4 2026 or early 2027, leading to reported acceleration in EP growth and market share gains. | Abbott's press releases, investor relations website, and future earnings calls. Data from the pivotal trial will be presented at TCT. | [] | [] |
| Traction of New Electrophysiology Products (Volt PFA & TactiFlex Duo Catheters) | The successful adoption and market share gains of Volt PFA and TactiFlex Duo catheters are critical for accelerating Abbott's Electrophysiology growth, offsetting LAA headwinds, and strengthening its competitive position. | Monitor management commentary on initial sales traction, physician adoption rates, and market share trends for Volt PFA (following full U.S. release in mid-August and Q4 Japan launch) and TactiFlex Duo (following broad U.S. launch in Q4). | Bullish: Reported EP growth acceleration (mid-teens or higher excluding LAA) and clear indications of market share gains in Q4 2026 and Q1 2027 earnings reports. | Abbott's Q4 2026 earnings call (expected January 2027) and subsequent investor presentations. | [] | [] |
| Progress and Details of Nutrition Business Spin-off | The planned separation of the nutrition business is a transformative strategic move. It is expected to accelerate Abbott's sales growth and expand its margin profiles, creating two more focused and valuable independent companies. | Monitor company announcements and SEC filings for updates on the separation process, including the final share distribution ratio, capital structures for both entities, and dividend plans. The separation is anticipated to be completed by the end of 2027. | Bullish: Clear communication of a definitive timeline, favorable share distribution ratio, and strong financial foundations for both companies, indicating smooth execution of the separation. | Abbott's official press releases, investor relations website (abbott.com), and SEC filings (e.g., Form 10-K, 8-K) as the process unfolds. The next earnings call in January 2027 will likely provide updates. | [] | [] |
| US Launch and Payer Coverage for Libre Duo (Dual Glucose Ketone Sensor) | Libre Duo, the world's first dual glucose ketone biowearable sensor, expands Abbott's innovative Libre platform, offering new monitoring capabilities for diabetes patients and potentially driving further growth in the diabetes care segment. | Observe the U.S. commercial launch of Libre Duo, expected in December 2026. Track initial market reception, physician prescribing patterns, and any announcements regarding payer formulary coverage, especially the significant payer coverage starting January 1, 2027. | Bullish: Successful U.S. launch with strong initial uptake and favorable payer coverage announcements, contributing to the overall diabetes care growth rate. | Abbott's press releases, investor relations updates, and the Q4 2026 earnings call for initial launch metrics and commentary on payer adoption. | 1. Google Trends — Search InterestNot in registry Metric/field Search term volume for 'Libre Duo' AND 'glucose ketone sensor' Cadence weekly Why it matters Indicates public and physician interest and awareness of the new product, signaling potential market adoption. Signal to watch Significant increase in search interest following the December launch. Confidence: Medium | [] |
Key Reported Metrics, Reratings Triggers & ResultsThis metric reflects Abbott's overall revenue performance. Management expects acceleration in Q4, which is crucial for validating their full-year outlook and se
Last reported · 2026-10-21
| Key reported metrics | Rerating thresholds | Earnings results | ||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Last period | Why it matters | What's needed for rerating | Rerating context | Earnings date | Actual reported | Hit target? | Notes |
| Comparable Sales Growth | 7% y/y growth | This metric reflects Abbott's overall revenue performance. Management expects acceleration in Q4, which is crucial for validating their full-year outlook and setting the tone for 2027 amidst the planned nutrition spin-off. | Comparable Sales Growth of at least 10.0% for Q3 2026, demonstrating significant acceleration from Q2's 4.8% and putting the company on track for the upper end of its 6.5%-7.5% full-year guidance. | Hitting this threshold would validate management's confidence in a strong second-half acceleration, driven by key segments like Nutrition, Electrophysiology, Core Lab, and Cancer Diagnostics. This performance would reinforce the bullish investment thesis, demonstrating Abbott's ability to deliver high-single-digit top-line growth and expand its competitive position through new product launches and market penetration, leading to a positive re-rating. | 7% y/y growth | No | Comparable sales grew 7% in Q3, accelerating from the prior quarter's 4.8% but missing the 10.0% rerating trigger. Management noted that the Q3 growth was in line with their expectations. However, the full-year guidance was reduced to approximately 6%, implying Q4 growth just above 8%. This adjustment was primarily due to short-term headwinds in Electrophysiology (LAA market dynamics) and Diabetes Care (penetration challenges and international pricing pressure). The company expressed confidence in accelerating growth for 2027, particularly after the planned nutrition business spin-off. | |
| Continuous Glucose Monitoring (CGM) Sales Growth | 8% y/y growth | This segment faces international pricing pressure and challenges in penetrating the Type 2 non-insulin market. The Q4 performance will indicate if the business can stabilize or improve with the Libre Duo launch. | Continuous Glucose Monitoring (CGM) Sales Growth needs to accelerate to at least 15% year-over-year for the upcoming earnings report on 2026-10-21. | This acceleration would signal that Abbott's new product launches, such as Libre Duo, and ongoing international reimbursement expansions are effectively driving growth beyond current rates. It would validate management's bullish outlook on the CGM segment's 'multibillion-dollar opportunity' and improve its competitive positioning against peers, leading to a positive revaluation. | 8% y/y growth | No | Continuous Glucose Monitoring (CGM) sales grew 8%, decelerating from the prior quarter's 9.5% and significantly missing the 15% rerating trigger. Management cited two main reasons for this: a harder challenge in penetrating the Type 2 non-insulin population without reimbursement expansion, and increased pricing pressure in international markets where Abbott holds significant market share. The company expects low to mid-single-digit growth for CGM in the near term but highlighted upcoming catalysts like the U.S. launch of Libre Duo in December and new payer formulary coverage starting January 1, 2027, which could reignite growth. | |
| Electrophysiology Sales Growth | 10.6% | New product launches like Volt PFA and TactiFlex Duo are expected to drive acceleration and overcome LAA market headwinds. Investors will monitor if these catalysts translate into stronger growth and market share gains. | ||||||
Key QuestionsWill the planned spin-off of the Nutrition business by the end of 2027 successfully accelerate Abbott's sales growth and expand its margin profile as anticipate
Will the planned spin-off of the Nutrition business by the end of 2027 successfully accelerate Abbott's sales growth and expand its margin profile as anticipated, and how will the separation-related costs and capital structuring impact the company's near-term financial performance?
- Question 2
Can Abbott's Diabetes Care segment overcome current headwinds from international pricing pressure and slower penetration of the Type 2 non-insulin market to accelerate CGM sales growth beyond the low to mid-single-digit range, particularly with the upcoming U.S. launch of Libre Duo and potential future Medicare coverage expansion?
- Question 3
Will the broad U.S. launch of the TactiFlex Duo catheter and the anticipated U.S. introduction of Amulet 360 effectively overcome short-term LAA market headwinds and drive significant market share capture and growth acceleration in Abbott's Electrophysiology business in the upcoming quarters?
Earnings Transcript Summary
· 2026Q3 Earnings Call
| 3 Things Management Is Most Focused On | Call Takeaway & Tone | Prior Quarter'S Y/Y Growth By Segment | 3 Things Analysts Most Pressed On (And Mgmt Responses) | Revenue Segments |
|---|---|---|---|---|
| 3 Things Management Is Most Focused On1. **Strategic Separation of Nutrition Business**: Management announced the intention to separate the nutrition business into an independent, publicly traded company, believing both Abbott and the nutrition business can create greater value and achieve maximum potential as independent organizations. 2. **Innovation and Pipeline Advancement**: Abbott is heavily focused on leveraging its innovation pipeline, highlighted by multiple new product approvals and launches (e.g., new blood-based colorectal cancer screening test, Similac infant formula with whole milk, TactiFlex Duo catheter, Amulet 360, Libre Duo), to strengthen its ability to deliver sustainable growth. 3. **Accelerating Growth and Expanding Margins for the Remaining Abbott Portfolio**: Following the separation, management expects Abbott's sales growth to accelerate and margin profiles to expand, repositioning the company into higher growth, higher margin businesses powered by technology and innovation. | Call Takeaway & ToneThe overall takeaway of the call was strategically transformative and confident, despite acknowledging some short-term headwinds. The tone was largely positive, with management emphasizing the significant strategic step of spinning off the nutrition business to unlock greater value for both entities. Abbott reported an acceleration in Q3 sales and earnings growth, driven by a robust and diversified innovation pipeline across its remaining MedTech, Diagnostics, and EPD segments. While management acknowledged short-term challenges in Electrophysiology and Diabetes Care, leading to a conservative initial outlook for 2027 sales, they expressed strong confidence in the company's long-term growth trajectory, margin expansion, and ability to generate strong cash flow and grow dividends. The focus remains on innovation as a key differentiator and strategic portfolio shaping for future success. | Prior Quarter'S Y/Y Growth By SegmentOverall comparable sales growth in Q2 2026 was 4.8%. Diagnostics sales increased 1.8% (Core Laboratory US grew 7.5%, Rapid and Molecular Diagnostics declined 8%, Cancer Diagnostics grew 13%). For Nutrition, the Q2 2026 earnings summary noted a sequential increase of $125 million and International Pediatric Nutrition growing 6.5%, but a total year-over-year percentage for the entire segment was not explicitly provided in the prior quarter's summary. Established Pharmaceutical Products (EPD) sales grew 9%. Medical Devices sales grew 8.5% (Cardiovascular Device Portfolio grew 8.5%, Electrophysiology growth accelerated with Europe up >20%, Rhythm Management grew 9.5%, Heart Failure grew 9%, Diabetes Care/Continuous Glucose Monitoring grew 9.5%). | 3 Things Analysts Most Pressed On (And Mgmt Responses)1. **Strategic Rationale for Nutrition Spin-off**: Robert Marcus from JPMorgan asked about the strategic rationale, timing, and why a spin-off versus a sale. Management responded that the decision stems from a belief in the huge opportunity in the healthy nutrition market, which the nutrition business can capitalize on better as an independent entity. They emphasized that a spin-off avoids tax implications of a sale and allows both companies to sharpen strategic and operational focus. 2. **NEC Liability and Revenue Guidance Reduction**: Larry Biegelsen from Wells Fargo inquired about the NEC liability post-spin and the drivers behind the revenue guidance reduction for the year, with implications for 2027. Management stated that resolving NEC litigation is not a prerequisite for completing the separation, and both companies will be well-capitalized. The Q4 revenue reduction was attributed to short-term headwinds in Electrophysiology (LAA market dynamics, accounts waiting for Amulet 360) and Diabetes Care (harder penetration of Type 2 non-insulin, international pricing pressure). For 2027, management expects sales to be similar to 2026 initially, with opportunities to move up. 3. **Pipeline Strength and Overlooked Innovations**: Patrick Wood from UBS asked about the forward pipeline, how it compares to the past, and what innovations might be overlooked by the market. Management expressed strong confidence in the pipeline, highlighting increased R&D spend and excitement for products like the AVEIR Conduction System Pacing leadless product, Cephea mitral replacement valve, IVL programs, Libre platform expansion (e.g., lactate sensor), and biosimilars in the EPD business, emphasizing a deliberate effort to invest in all the right areas for sustained growth. | Revenue SegmentsSales grew 7% in the third quarter. Diagnostics sales grew 6.5%, driven by Core Laboratory sales growth of 5.5% and Cancer Diagnostics sales growth of 14%. Nutrition sales grew 5%, with U.S. pediatric nutrition sales growing 11% and adult nutrition sales increasing 2% (U.S. adult nutrition up 3.5%). Established Pharmaceutical Products (EPD) sales increased 8.5%. Medical Devices sales grew 8%, led by double-digit growth in electrophysiology and rhythm management (electrophysiology mid-teens or high teens excluding LAA, rhythm management 10%, diabetes care/CGM 8%). |
· 2026Q2 Earnings Call
| 3 Things Management Is Most Focused On | Call Takeaway & Tone | Prior Quarter'S Y/Y Growth By Segment | 3 Things Analysts Most Pressed On (And Mgmt Responses) | Revenue Segments |
|---|---|---|---|---|
| 3 Things Management Is Most Focused On1. Accelerating sales growth in the second half of 2026: Management is highly confident in achieving this acceleration, driven by Nutrition, Electrophysiology, Core Lab, and Cancer Diagnostics, citing building momentum and clear line of sight to key drivers. 2. Gross margin expansion and strong cash generation: The company is focused on disciplined execution of margin expansion initiatives through favorable business mix and operational improvements, which allowed them to raise full-year EPS guidance. 3. Robust pipeline and new product launches: Management highlighted recent pipeline achievements and anticipated launches over the next 12 months, including Amulet 360, Libre Duo, Tactiflex Duo PFA, a balloon expandable TAVR valve, and a mitral replacement valve, which are expected to sustain growth into 2027 and beyond. | Call Takeaway & ToneThe overall takeaway of the call was highly positive and confident. Management reported accelerated sales growth in Q2 2026, exceeding expectations, and reaffirmed full-year sales guidance while raising EPS guidance. The tone was optimistic, emphasizing strong momentum building across the portfolio, particularly in Nutrition, Electrophysiology, Core Lab, and Cancer Diagnostics, which are expected to drive significant acceleration in the second half of the year. Management also highlighted a robust pipeline of innovative products anticipated to launch over the next 12-24 months, ensuring sustainable long-term growth. The company feels well-positioned to achieve its high-single-digit top-line and double-digit bottom-line growth targets. | Prior Quarter'S Y/Y Growth By SegmentOverall comparable sales growth: 3.7%. Diagnostics sales: 1.8% (Core Laboratory: 3%, Rapid and Molecular Diagnostics: declined 10%, Cancer Diagnostics: 13%). Nutrition sales: declined 7.7%. Established Pharmaceutical Products (EPD) sales: 9.0%. Medical Devices sales: 8.5% (Electrophysiology: 13%, Heart Failure: 12%, Rhythm Management: 13%, Diabetes Care (Continuous Glucose Monitoring): 7.6%). | 3 Things Analysts Most Pressed On (And Mgmt Responses)1. US procedure volumes and confidence in H2 acceleration: Robert Marcus from JPMorgan asked about potential deceleration in US procedure volumes. Management responded that they are not seeing signs of deceleration, citing strong diagnostic testing volumes, robust US Core Lab business growth (hospital labs up 13%), and the inelastic demand for high-acuity, life-saving products, particularly among Medicare beneficiaries. They expressed high confidence in H2 acceleration, driven by Nutrition, EP, Core Lab, and Cancer Diagnostics. 2. Libre trends, CGM outlook, and timing for new products/coverage: Larry Biegelsen from Wells Fargo inquired about Libre's growth, the outlook for the CGM business, and the timing of US approval for Libre Duo and Type 2 non-insulin coverage. Management acknowledged the 9.5% growth but emphasized the significant long-term opportunity with only 15 million out of 75-80 million potential CGM users globally. They highlighted ongoing reimbursement expansion discussions in large markets, which are expected to drastically accelerate growth when finalized, and mentioned planning for a fifth manufacturing facility due to strong market belief. 3. Exact Sciences (Cancer Diagnostics) performance and future leadership in blood tests: Vijay Kumar from Evercore ISI pressed on the visibility of Caregap programs driving H2 acceleration for Exact Sciences and Abbott's strategy to be a market leader in blood-based colorectal cancer screening. Management confirmed strong visibility into Caregap programs, which tend to ramp in H2 due to health systems focusing on HEDIS and star ratings. They stated their aim is to be the overall leader in screening, offering both best-in-class stool (Cologuard) and blood tests, viewing the blood test as an opportunity to bring more patients into the screening funnel and educate them on Cologuard's benefits. | Revenue SegmentsOverall comparable sales growth: 4.8%. Diagnostics sales increased 1.8% (Core Laboratory US grew 7.5%, Rapid and Molecular Diagnostics declined 8%, Cancer Diagnostics grew 13%). Nutrition sales increased sequentially by $125 million, with International Pediatric Nutrition growing 6.5%. Established Pharmaceutical Products (EPD) sales grew 9%. Medical Devices sales grew 8.5% (Cardiovascular Device Portfolio grew 8.5%, Electrophysiology growth accelerated with Europe up >20%, Rhythm Management grew 9.5%, Heart Failure grew 9%, Diabetes Care (Continuous Glucose Monitoring) grew 9.5%). |
Transcript Tidbits
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Broader Themes Emerging | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|---|
| About Expanding Eligible MarketAbbott announced its intention to separate its nutrition business into an independent, publicly traded company, which is expected to capitalize on the growing demand for healthy nutrition. This new nutrition company is projected to be the largest globally scaled pure-play company in the healthy nutrition market. Abbott launched its first blood-based colorectal cancer screening test in September, expanding screening options for healthcare providers and patients. The TactiFlex Duo catheter received FDA approval earlier than anticipated, enabling a broad U.S. launch in the fourth quarter. The company also received CE Mark for its new Amulet 360 left atrial appendage device, with plans to introduce this technology to the U.S. market. FDA approval for Libre Duo, the world's first dual glucose ketone biowearable sensor, was secured in August, with a U.S. launch expected in December. Abbott's Established Pharmaceutical Products (EPD) business continues to demonstrate strong growth across emerging markets. The company is expanding the Libre platform into other analytes, with a lactate sensor currently entering trials. The biosimilars pipeline within the EPD business presents a significant opportunity in emerging markets where originator products are often unavailable. The cancer diagnostic business is set to introduce new personalized diagnostic tests, with data on its MRD test scheduled for presentation at ESMO. International expansion for cancer diagnostics is also underway, with specific markets already identified. In diabetes care, Abbott anticipates a benefit in the U.S. from a significant payer formulary coverage change that will take effect on January 1. | About CompetitionAbbott is uniquely positioned as the only company offering both stool-based and blood-based colorectal cancer screening options. In the electrophysiology (EP) market, LAA market dynamics are creating a short-term headwind, with a competitor having previously discussed market challenges. Despite this, Abbott aims to capture market share in Europe for electrophysiology. In international diabetes care markets, where Abbott holds a significant 50%-70% market share, the company is experiencing increased pricing pressure. Abbott plans to defend its market share position in these international diabetes markets by implementing pricing adjustments and securing longer-term contracts. The company believes its Amulet 360 device offers a superior seal technology compared to competitive products. Cologuard is noted for its better performance in earlier detection, particularly for precancerous lesions, compared to current blood-based tests. Abbott's blood test for colorectal cancer has a different margin profile due to its partnership model. The company is considering pricing strategies in the broader cancer screening market, suggesting that current high rates for blood tests may limit widespread adoption. In the LAA market, a competitor currently holds a dominant 90% market share. | About The Broader IndustryThe nutrition market has undergone a significant transformation, shifting from being primarily a healthcare market influenced by professionals to one increasingly shaped by consumer preferences, wellness trends, and retail execution. There is a growing demand for healthy nutrition, driven by consumers' increasing recognition of metabolic health and the role of nutrition in disease prevention. Abbott's portfolio is strategically aligned with durable healthcare trends, including an aging global population, the rising prevalence of chronic diseases, and an increasing demand for earlier diagnosis and more personalized treatments. Diagnostic test volume data, collected from thousands of instruments globally, indicates strong and stable underlying demand for healthcare services more broadly. The rise of GLP-1 users is influencing a strong focus on protein in nutrition products across the industry. The litigation environment concerning NEC liability is showing signs of shifting, with Abbott having prevailed in several federal MDL cases. The company highlighted that the implementation of care gap programs is crucial for health systems, as it contributes to their star ratings and Medicare CMS rebates. The continuous glucose monitoring (CGM) market has not experienced significant new reimbursement expansion for a considerable period. For the cancer screening market to truly expand, Abbott believes broader adoption is necessary, which may require adjustments to current pricing strategies for blood tests. The process for establishing CMS reimbursement for new tests, such as Cologuard Plus, differs from that of established tests. Clinical data strongly supports the value of CGM use in type 2 non-insulin patients as a behavior modification tool. | Where Things Are HeadedAbbott plans to separate its nutrition business into an independent, publicly traded company by the end of next year. Following this separation, Abbott anticipates an acceleration in its sales growth and an expansion of its margin profiles. The new nutrition company is expected to qualify for inclusion in the S&P 500. Post-separation, Abbott will remain one of the largest, most diversified, and fastest-growing healthcare companies globally. Abbott's financial profile after the separation is projected to show a 50 to 100 basis point acceleration in sales growth, a gross margin increase of over 200 basis points, and an operating margin increase of approximately 100 basis points. The company forecasts adjusted earnings per share (EPS) of $1.62 to $1.67 for the fourth quarter. Separation-related costs are expected to be incurred but will be treated as specified items and excluded from adjusted earnings. Both Abbott and the new nutrition company will pay a dividend that, when combined, will equal Abbott's current dividend at the time of separation. Abbott expects to reignite growth in the LAA market with the introduction of Amulet 360. The Volt PFA catheter is slated for launch in Japan during the fourth quarter. The TactiFlex Duo catheter will see a full launch in the fourth quarter. Libre Duo is scheduled for a U.S. launch in December. Abbott anticipates an acceleration in its total company growth rate in 2027, though it plans to adopt a more conservative approach to initial guidance. The company intends to continue increasing its R&D spend into the next year. Abbott expects to present data on its MRD test at ESMO. The peripheral IVL trial is expected to commence at the end of the year. In the short term, Abbott maintains capacity for tuck-in M&A deals. The final significant debt paydown related to the St. Jude and Alere acquisitions is scheduled for this year. | Updates On ThemeDiagnostics | Broader Themes EmergingThe increasing consumer focus on metabolic health and the role of healthy nutrition in disease prevention is driving a significant evolution in the nutrition market, shifting it towards consumer preferences and wellness trends. The strategic repositioning of portfolios by traditional food companies towards healthier options, mimicking Abbott's existing nutrition portfolio, indicates a broader industry trend. The ongoing trend of an aging population and increasing prevalence of chronic diseases continues to drive demand for healthcare solutions, particularly earlier diagnosis and personalized treatment. The impact of GLP-1 users is influencing product development in nutrition, specifically a strong focus on protein. The challenges and complexities of cybersecurity events are a recurring theme across industries, including healthcare, requiring robust mitigation strategies. | Bullish-Leaning Quotes (Short)Sales grew 7% in the third quarter, and earnings per share grew 9%, representing an acceleration in growth on both top and bottom lines. We announced our intention to separate our nutrition business into an independent, publicly traded company. Abbott will remain one of the largest, most diversified and fastest-growing healthcare companies in the world. We expect Abbott's sales growth to accelerate and margin profiles to expand. Innovation continues to be a key differentiator for Abbott. I have tremendous confidence in Abbott's future as an innovation-driven healthcare company. Our testing data continued to support that view, with testing demand remaining healthy and at durable levels. In cancer diagnostics, sales growth of 14% was driven by Cologuard. We launched our first blood-based colorectal cancer screening test. EPD, where sales increased 8.5% in the quarter. Medical devices, where sales grew 8%. Growth in the quarter was mid-teens or high teens when excluding LAA. We expect to execute a broad U.S. launch starting in the fourth quarter. We received FDA approval earlier than expected for our TactiFlex Duo catheter. We received CE Mark for our new Amulet 360 left atrial appendage device. Expanding use of AVEIR is occurring in both the U.S. and international markets. We received FDA approval for Libre Duo, the world's first dual glucose ketone biowearable sensor. We delivered an acceleration in growth on both top and bottom lines. We expect Abbott's financial profile to reflect an acceleration in the sales growth and increased profitability. Gross margin as a percent of sales to increase by more than 200 basis points. Operating margin as a percent of sales to increase by approximately 100 basis points. I find it very hard to imagine that when the process is done, that the reimbursement rate for Cologuard Plus would go down. We've got a very competitive product that not only has added some ease of use to its implant, but it also maintains what we believe is a superior seal technology there. I think this is an interesting category. It's a $1 billion-plus market that's growing. Our balance sheet is in very good, great shape. | Bearish-Leaning Quotes (Short)In EP, we're facing some short-term headwind from the dynamics related to the LAA market. There was almost like an immediate slowdown in orders here in the U.S. as I think accounts are waiting for the new product. I expect that growth rate to be in that low to mid-single range. That change really reflects, I think, two things. One of them is a little bit of a harder challenge in penetrating the type 2 population in absence of the reimbursement expansion. I think the other element that we're seeing is a little bit more pricing pressure in the international markets. I think our pricing actions here that we're going to have to take internationally are going to kind of mute a little bit of the volume growth that we're seeing. I think for 2027, I think we'll set our guidance that's going to create opportunity for us to move up from there in January. I'd say the biggest driver of that delta versus expectation there was the cybersecurity event that we had in July. Those blips, which lasted about 7-10 days, that cost us about a point of growth. I find it difficult to believe that you'll get the kind of uptake in any kind of blood type test at these rates. We just got to be careful about how these things are promoted and how the accuracy of the information that's being portrayed to the consumer is complete and transparent and some of the deficiencies that the blood still has. It's just right now, the detection on the precancerous lesion side is not as good as what Cologuard is. | HiringThe new nutrition company will have approximately 16,000 employees. Daniel Salvadori, Executive Vice President and Group President of Established Pharmaceuticals and Nutrition Products, will become Chief Executive Officer of the new nutrition company, joined by an experienced leadership team. Robert Ford specifically chose the term 'battle tested' to describe the nutrition team, highlighting their resilience and dedication. |
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Broader Themes Emerging | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) |
|---|---|---|---|---|---|---|---|
| About Expanding Eligible MarketAbbott anticipates launching three new products, including the Amulet 360 left atrial appendage device and Libre Duo (the world's first dual glucose ketone monitoring sensor), in the US at a steady cadence over the next 12 months. The company is also on track to begin patient enrollment in Q4 for several important clinical trials that will support future product launches, such as a balloon expandable TAVR valve, a leadless conduction system pacing device, a mitral replacement valve, a peripheral IVL device, and a wearable continuous lactate monitoring sensor. In diabetes care, the US type 2 non-insulin market for continuous glucose monitoring (CGM) represents a huge opportunity, potentially unlocking around 10 million Medicare beneficiaries and accelerating commercial insurance coverage, which could be a multibillion-dollar opportunity. Internationally, Abbott is in active discussions with about a dozen countries to introduce or expand CGM reimbursement. Cancer diagnostics growth is benefiting from a growing base of both new and repeat Cologuard users, care gap programs, and continued international adoption. The EPD business is experiencing growing demand for healthcare in emerging markets due to evolving market dynamics, including expanding access to healthcare, aging populations, and a rising need to treat both acute and chronic conditions. Abbott also sees opportunities for market development in the left atrial appendage (LAA) closure market, not just within electrophysiology (EP) but also in interventional cardiology. | About CompetitionAbbott's Cologuard is highlighted for its market-leading accuracy and superior ability to detect cancer at earlier stages compared to other available tests. Regarding blood tests for colorectal cancer screening, Abbott acknowledges that they do not have the same sensitivity as Cologuard for detecting precancerous polyps and earlier stage cancer, but the company aims to be a leader in screening by offering both best-in-class stool and blood tests. In the EP market, Abbott is focused on maintaining its mapping superiority as competitors launch their own mapping systems. The company noted an increase in competitive intensity in the US mitral space within its Structural Heart unit. In the LAA closure market, Abbott's competitor holds a 90% market share, and Abbott's focus with the Amulet 360 is on market share capture. In adult nutrition, Abbott noted that some competitors' high-protein products taste well due to high sugar content, differentiating Abbott's focus on high protein and lower sugar. | About The Broader IndustryDiagnostic test results inform approximately 70% of all healthcare decisions, making testing volumes a reliable barometer of overall healthcare activity and demand. Abbott's test volume data reflects strong and stable demand for testing globally, indicating durable underlying demand for healthcare. The company addressed investor concerns about decelerating procedure volumes in the US, stating that their data does not show a decline, particularly in diagnostic volumes and US Core Lab business, which accelerated growth. Abbott believes that challenges with ACA lower enrollment or Medicaid disenrollment are a flawed assumption for the med tech diagnostic space, as Medicare, not Medicaid, is the largest US payer for devices, driving over two-thirds of Abbott's US cardio business. Demand for high-acuity, life-saving products is considered inelastic, meaning patients with serious acute medical conditions are treated regardless of insurance status. The aging population, with 10,000 people turning 65 daily in the United States, is identified as a global driving factor for healthcare demand. The rise of GLP-1 users is influencing a strong focus on protein in nutrition products. | Where Things Are HeadedAbbott is reaffirming its full-year guidance for comparable sales growth of 6.5% to 7.5% and raising its EPS guidance range to $5.45 to $5.60, expressing high confidence in a second-half acceleration driven by Nutrition, Electrophysiology (EP), Core Lab, and Cancer Diagnostics. The company anticipates launching several new products, including Amulet 360, Libre Duo, and Tactiflex Duo PFA catheter, over the next 12 months. Abbott expects cancer diagnostics growth in the second half of the year to be higher than the first half, supported by increasing volumes from care gap programs, recently launched tests, and continued international adoption. The EP business is expected to begin outperforming the market and recapturing share in the second half, with momentum carrying into next year, boosted by the launch of the Amulet 360 LAA device. Abbott is planning for a fifth manufacturing facility for Libre sensors, a billion-dollar investment, to meet future capacity needs, indicating strong long-term confidence in the CGM market. The company targets high single-digit top-line growth and double-digit bottom-line growth, with 7% as a sustainable growth rate for the overall portfolio. Structural Heart is expected to return to a mid- to high-single-digit growth rate by the end of the year, with significant pipeline contributions anticipated in 2029-2030. | Updates On ThemeDiagnostics | Broader Themes EmergingThe increasing global prevalence of chronic diseases, particularly diabetes, cardiovascular conditions, and cancer, combined with an aging population, creates a sustained and growing demand for advanced diagnostic solutions and proactive health monitoring. The discussion around GLP-1 users is influencing the demand for high-protein, low-sugar nutrition products across the industry. | Bullish-Leaning Quotes (Short)Sales growth of 4.8% which represents an acceleration compared to the previous 2 quarters. reaffirming our full year guidance for comparable sales growth of 6.5% to 7.5% and raising our EPS guidance range to $5.45 to $5.60. Our test volume data... continues to reflect strong and stable demand for testing. We view this as a positive indication of the durable underlying demand for healthcare, not just in the US, but globally. Abbott is now the market leader in both WIC and non WIC segments. EPD to sustainably deliver high single digit sales growth. I am feeling very confident, as I have said. we are probably in the final stages here of, planning for a fifth manufacturing facility. I expect global EP growth to accelerate. I actually think now with this product, we have the potential to actually make that a reality. | Bearish-Leaning Quotes (Short)rapid and molecular diagnostics, sales declined 8% driven by the anticipated decrease in respiratory testing, as a result of a weaker than normal season that concluded during the second quarter. The challenge, Larry, is actually trying to pinpoint the exact month or quarter as to when that reimbursement expansion is gonna happen. blood tests... does not have the same sensitivity as it relates to detection of precancerous polyps and earlier stage detection. I have been I have been pretty clear about where we are falling short. it is not a price issue. it is not a product issue. it is really kinda how we think about, you know, how we think about competing in the mitral space, specifically in the US. The competitor has a 90% market share. |
Notes
| Date | Comment | Comment Type | Comment Sentiment | Link | Price Reaction |
|---|---|---|---|---|---|
| 2026-07-16 | Abbott reported strong Q2'26 results with accelerated sales growth and an EPS beat, leading to raised full-year EPS guidance. Management expressed high confidence in H2 acceleration driven by Nutrition, EP, Core Lab, and Cancer Diagnostics, alongside a robust pipeline. The market reacted very positively, with the stock gaining 12.78% (outperforming SPY), aligning with the optimistic outlook and strong guidance. | Earnings Transcript | Positive | +12.78% (vs SPY: +14.31%) | |
| 2026-10-21 | Abbott announced a strategic nutrition business spin-off by late 2027, aiming to accelerate growth and expand margins for the remaining MedTech, Diagnostics, and Pharma portfolio. Q3 sales grew 7%, and EPS grew 9%, with strong innovation across segments. Despite Q4 headwinds in EP and Diabetes, the market perceived the news positively, with the stock outperforming SPY (1.22% vs. 0.19%), aligning with the long-term value creation message. | Earnings Transcript | Neutral | +1.22% (vs SPY: +1.03%) |
Upcoming Events
| Catalyst ID | Estimated Timing | Estimated Date Start | Estimated Date End | Catalyst | Why It Matters | Ticker Or Theme Specific | Transcript Date | Source Type |
|---|---|---|---|---|---|---|---|---|
| ABT_6009f906 | in December | 2026-12-01 | 2026-12-31 | U.S. launch of Libre Duo, the world's first dual glucose ketone biowearable sensor. | This product allows people with diabetes to monitor ketones without traditional blood or urine tests, offering a new growth driver for the diabetes care business. | Ticker | 2026-10-21 | earnings_transcript |
| ABT_c375ff52 | January 1 | 2027-01-01 | 2027-01-01 | Significant U.S. payer formulary coverage for Libre goes into effect. | This expanded coverage is expected to be a nice growth driver for the diabetes business in the coming year. | Ticker | 2026-10-21 | earnings_transcript |
| ABT_79370e41 | in the fall | 2026-09-01 | 2026-11-30 | Potential Medicare coverage expansion for Libre Continuous Glucose Monitoring (CGM) for Type 2 non-insulin users in the US. | This could unlock a multibillion-dollar opportunity by accelerating commercial insurance coverage and reaching approximately 10 million Medicare beneficiaries, significantly boosting CGM sales. | Ticker | 2026-07-16 | earnings_transcript |
| ABT_30e24e43 | by year-end 2026 | 2026-10-01 | 2026-12-31 | FDA approval and US launch of Amulet 360 Left Atrial Appendage (LAA) device. | This device is designed to help reduce the risk of stroke in patients with AFib and is expected to reignite growth and capture market share in the LAA closure market. | Ticker | 2026-10-21 | earnings_transcript |
| ABT_7cc559f2 | starting in the fourth quarter | 2026-10-01 | 2026-12-31 | Broad U.S. launch of TactiFlex Duo catheter. | This catheter enables physicians to seamlessly switch between using RF and PFA energy during a procedure, which is expected to drive adoption and market share in electrophysiology. | Ticker | 2026-10-21 | earnings_transcript |
| ABT_8bb43b0e | sometime in Q4 | 2026-10-01 | 2026-12-31 | Launch of Volt PFA catheter in Japan. | This launch is expected to turn Japan from a headwind to a tailwind for the electrophysiology business, contributing to international growth acceleration. | Ticker | 2026-10-21 | earnings_transcript |